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A B S T R A C T
Fever in returning travelers is a common problem and usually the diagnosis is made within a few days or
the traveler recovers.
We present two travelers who presented with fever two weeks after returning from a six week
vacation in South America. Over the following 18 months they presented with short attacks of fever,
elevated CRP and leukocytosis and the program for investigation became more and more elaborate. A
curious and key feature was, that they were completely synchronous both developing symptoms within
an hour and presentation with the same laboratory ﬁndings of leukocytosis and elevated CRP. Extensive
and repeated tests were performed, at our facility and abroad. After a year it was discovered that the uses
of aroma oils were associated with the symptoms. No similar case has been found to be reported
previously.
These cases emphasize that natural products are not inherently safe. The investigational program was
build up over time as new attacks continued to occur and suggestions from different centers which were
consulted were followed up. The number of tests performed at different laboratories took an extensive
amount of time. These cases emphasize that a panel of analysis in returning travelers in which no clear
diagnosis is found should be developed.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fever in returning travelers is a common problem and usually the
diagnosis is made within a few days or the traveler recovers [1,2].
We report here two travelers who presented with fever two
weeks after returning from a six week vacation in South America.
Over the following 18 months they presented with short attacks of
fever, elevated CRP and leukocytosis and the program for
investigation became more and more elaborate. A curious and
key feature was, that they were completely synchronous both
developing symptoms within an hour and presentation with the
same laboratory ﬁndings of leukocytosis and elevated CRP.
Extensive and repeated tests were performed. After about a year
it turned out that the couple used aroma oils (Nature and
Decouvertes – Fig. 1) in the home applied by a nebulizer placed in
the middle of a table. The use of the oil matched perfectly with the
fever attacks. The oils were not used during summer, also
explaining the absence of symptoms during the summer months.* Corresponding author. Present address: Department of Gynaecology and
Obstetrics, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, 8200 Aarhus
N, Denmark. Tel.: +45 28587858.
E-mail addresses: berit.booth@auh.rm.dk (B.B. Booth),
joepeter@rm.dk (E. Petersen).
http://dx.doi.org/10.1016/j.idcr.2015.03.002
2214-2509/ 2015 The Authors. Published by Elsevier Ltd. This is an open access articl
4.0/).Aromatic oils have been used for centuries as healing and
soothing scents.
Since the use of the oils ended there has been no relapse in any
symptoms. It has not been possible to test them with exposure for
ethical reasons.
We are not aware of or have found any previous reports, in
English or other languages, reporting similar events after the use of
similar products.
Case presentation
After traveling to South America for a six weeks tourist holiday
the two patients returned home to Denmark. Ten days after
returning they were both admitted to hospital with fever, muscle
and joint pains and vomiting. From the 8 September 2012 to the 22
October 2012 they spent 3 weeks in Peru, half a week in Bolivia,
half a week in Chile and 2 weeks in Brazil. They traveled by local
busses, stayed at medium level hotels and were not ill at any time
during their travels.
Prior to their travels they had received vaccines against
hepatitis A and B, yellow fever and tetanus/diphtheria. Table 1
shows the patients’ history and Table 2 lists CRP, white blood cell
count and recorded rectal temperatures. Day 0 is deﬁned as the
ﬁrst day the couple was admitted to hospital, 10 days after thee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Aroma oils used by the patients.
Table 1
Symptom history.
Day Symptoms
0 Fever, joint and muscle pain
10 Vomiting, headache, muscle pain, fever
20 Night sweats, shivering, headache, light respiratory pain
112 Fever, night sweats, shivering, muscle and joint pain, slight
non-productive cough
127 Muscle and joint pain
136 Fever, night sweats, shivering, headache
139 Fever, muscle and joint pain
412 Fever, muscle and joint pain
434 Fever, chest pain, dyspnea, tiredness
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time and the total IgE remained normal throughout.
Approximately nine episodes occurred within the following 18
months, all attacks being identical in symptoms, duration and
paraclinical results for both patients (Table 2).
Initially the patients were tested negative for malaria and
dengue fever. Under the suspicion of a rickettsial infection they
were treated with doxycycline 100 mg two times daily initially for
one week [3]. This was immediately afterwards repeated again for
one week. After the third relapse, Day 20, the patients received 3
months Doxycycline 100 mg two times daily plus moxiﬂoxacin
400 mg  1, as it was believed they previously had had a good
effect.
The patients went through an elaborate program of serological
tests and test for nucleic acids of different pathogens, which is
summarized in Table 3. Through the whole course a wide range of
tests were performed including heart echocardiography, PET-CT
and an MRI which were all normal.
Discussion
Deﬁnition of travel associated disease ‘‘is a patient who has
crossed an international boarder within the past 10 years and
presents for a presumed travel-related disease’’ [4]. It is not
uncommon for travelers to report an illness associated with theirTable 2
Biochemical infectious markers.
Day Patient A 
Temperature (8C) CRP (mg/l) WBC (10*9/l) 
0 37.5 58 32.2 
3 19.9 6.5 
10 37.1 36.6 25 
12 
13 11 5.3
24 1 4.6 
40 4.4 6.3 
112 26.3 18.2 
119 6.8 5 
127 5.7 15.8 
129 24.3 6.4 
153 <0.6 8.1
166 <0.6 7.7
194 
196 17 5
395 44.5 17 
412 0.6 7.6
434 37.1 20.5 24 
435 38.1 10.8travels (20–70%), but only a small portion of these actually seek
medical attention [2,5,6]. A detailed medical history is a very
important tool in correct diagnosis, including destinations, risk
factors, previous medical history. Incubation time is also important
to keep in mind through the process (Table 5) [2,5,7].
The GeoSentinel surveillance program has found that the most
common causes of fever after traveling is malaria, dengue fever,
enteric fever (Salmonella typhi) and rickettsioses [2]. Initially
malaria and dengue fever were excluded and the patients were
treated with doxycycline under the presumption of a rickettsia or
bartonella infection. When the fever attacks continued we
excluded endocarditis due to Coxiella burnetii (Q fever) and looked
for South American trypanosomiasis due to Trypanosoma cruzi
(Chagas disease), which can be transmitted orally through fresh
fruit juice. We speculated that Toxoplasma gondii was a possibility
as T. gondii genotypes in South America are more pathogenic
compared to Europe [8], but only one of the subjects had antibodies
at a low titer, not compatible with an acute infection. Leptospirosis
was also a diagnostic option, especially with a second phase of
fever shortly after the ﬁrst; this was however also excluded by a
negative serology. Acute schistosomiasis and other parasites were
ruled out as there was no eosinophilia or elevated total-IgE in
either patient.
Different centers were asked to assist with this case, including
Unite´ Des Rickettsies, France, Porton Down, UK and Center for
Disease Control and Prevention (CDC), United States. See Tables 3
and 4 for list of all the test and results found on the patients.
Everything that was tested for came out negative, including blood
and urine cultures.Patient B
Temperature (8C) CRP (mg/l) WBC (10*9/l)
37.7 67.2 34.9
26.1 6.7
37.2 40.6 24.8
26.8 8.2
0.9 6.2
<0.6 5.9
59 22.7
24.4 5.5
22.4 18.5
48.3 5.5
1.2 4.8
60.2 18.5
15.9 18.6
Table 3
Test results.
Day Test Result
Patient A Patient B
12 Borellia burgdorferi (IgM + IgG) Negative Negative
Bartonella henseale and B. quintana (IgM + IgG) Negative Negative
Ehrlichia (IgG) Positive Negative
Francisella tularensis Negative Negative
Rickettsian rickettsii, R. typhi (IgM + IgG) Negative Negative
Leptospira (patoc, icterohaemorrhagiae, interro. Copenhageni, canicola, interro. Autumnalis,
Hardjo, Pomona, Bataviae, Borgpeters. Tarassovi, Borgpeters. Ballum, Broomii)
Negative Negative
Brucella melitensis and B. abortus Negative Negative
40 Bartonella henselae and B. quintana Negative Negative
112 Francisella tularensis Negative Negative
Borellia burgdorferi (IgM + IgG) Negative Negative
Rickettsia DNA Negative Negative
Rickettsian rickettsii and R. typhi (IgM + IgG) Positive IgM for R. rickettsii Negative
Bacterial DNA (PCR) Negative Negative
Ehrlichia (IgG) Positive Negative
Bartonella henselae, B. quintana, B. bacilliformis* Negative Negative
Coxiella burnetii (IgM + IgG phase I and II) Inconclusive Negative
Rickettsia conorii, R. felis, R. typhi* Negative Negative
Bartonella PCR* Negative Negative
Brucella melitensis, B. abortus Negative Negative
129 Bacterial DNA (PCR) Negative Negative
164 Mayaro Virus RNA** Negative Negative
Borrelia burgdorferi** Negative Negative
Chikungunya Virus** Negative Negative
Rickettsia** Negative Negative
188 Oropouche Virus** Negative Negative
196 Leishmaniasis + Trypanosoma cruzi antibodies Negative Negative
395 Bacterial DNA (PCR) + Parasite DNA (PCR) Negative Negative
Bartonelle henselae (IgM + IgG), B. quintana (IgM + IgG) Negative Negative
434 Rickettsia Negative Negative
Bacterial DNA (PCR) Negative Negative
Trypanosoma cruzi, Trypanosoma brucei gambiense, T. brucei rhodensiense Negative Negative
Leishmania antibodies Negative Negative
Coxiella burnetti (Q-fever) antibodies Negative Negative
* Tested at Unite´ Des Rickettsies, France.
** Tested at Porton Down, UK.
Table 4
Laboratory results from Aarhus University Hospital, Denmark.
Day Test Result
Patient A Patient B
0 Microscopy for malaria Negative Negative
0 Dengue rapid test Negative Negative
0 Blood cultures  4 Negative Negative
10 Microscopy for malaria and Borrelia recurrentis Negative Negative
10 Blood cultures  2 Negative Negative
11 Microscopy for malaria and B. recurrentis Negative Negative
12 Microscopy for malaria and B. recurrentis Negative Negative
112 Blood cultures  2 Negative Negative
112 Cervical swab Negative –
112 Swap for Chlamydia + gonococci PCR and culture Negative –
119 Microscopy for malaria Negative Negative
127 Blood cultures  2 Negative Negative
129 Toxoplasma gondii IgM + IgG Negative Positive (IgG 85 UI/ml)
129 Mycobacterium tuberculosis interferon release assay Negative Negative
129 Blood cultures  2 Negative Negative
129 HIV antibody and antigen test Negative Negative
129 Syphilis Negative Negative
129 EBV serology Previous infection (EBNA IgG positive) Negative
129 CMV serology Previous infection (IgG positive) Negative
304 HIV antibody and antigen test Negative –
304 HAV, HBV; HCV Negative
395 HIV Negative Negative
395 Toxoplasma gondii IgM + IgG Negative Positive (IgG 92 UI/ml)
412 Swap for Chlamydia DNA + Gonococci culture Negative –
434 Mycobacterium tuberculosis Negative Negative
434 HIV antibody and antigen test Negative –
434 Toxoplasma gondii IgM + IgG Negative Positive (IgG 84 UI/ml)
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Table 4 (Continued )
Day Test Result
Patient A Patient B
435 Urine culture Negative –
435 Blood culture  2 Negative –
440 HIV (routine test in pregnancy) Negative –
440 Syphilis (routine test in pregnancy) Negative –
Table 5
Incubation period.
Disease Incubation time
Dengue fever 3–14 days
Leptospirosis 4–14 days
Borrelia 5–15 days
Francisella 1–14 days
Bartonella bacilliformis/Oroya fever 1–3 weeks
Rickettsia 10–14 days
Malaria 8–30 days
Q fever/Coxiella 2–3 weeks
Brucella 2–4 weeks
Syphilis Primary 3–90 days
Chagas disease/Trypanosoma cruzi Acute: immediate,
chronic: >8 weeks
Leishmaniasis >1 week
Epstein Barr virus
HIV
Tuberculosis
Cytomegalovirus
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as they are a common cause to fever of unknown origin in adults
[9]. HIV and other sexually transmitted diseases were also
screened for and these results were also negative. The patients
were not tested for histoplasmosis as this rarely causes a prolonged
course of disease in immunocompetent patients [10].
Throughout the long period of symptoms with this couple it
became more and more apparent that it was not an infectious
agent at play. Their symptoms and blood test were too synchro-
nized. The attacks were short lived and the CRP and leukocytosis
normalized within a few days. Malignancy and inﬂammatory
diseases were also ruled out as the cause of the recurrent fever.
Both patients had a slight dry cough and small, non-tender, lymph
glands at several stations. There was no rash. One would expect the
patients to react differently to the same infectious agent as their
immune systems are different as they differ genetically.
We, therefore, started searching for an agent they could both be
exposed to in the home. All the symptoms seemed to occur during
autumn, winter and spring – during which the windows are closed.
It is therefore believed to be repeated exposure to aroma oils
(Nature and Decouvertes) that is the cause of the symptoms. Since
the exposure has stopped there have been no more events. For
ethical reasons it has not been possible to test with expose.
The story emphasizes that natural products are not inherently
safe. The oils used here were nebulized and we assume that thetwo patients inhaled a high concentration of the nebulized oils
over a short time. This was actually recommended by the
manufacturer and the oils and table top nebulizer was purchased
together. As mentioned earlier, we are not aware of reports of any
similar events after using other similar products.
The investigational program was build up over time as new
attacks continued to occur and suggestions from different centers
which were consulted were followed up. The number of tests
performed at different laboratories took time and emphasizes that
a panel of analysis in returning travelers with continued symptoms
but without a clear diagnosis should be developed.
Conﬂicts of interest
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Patient consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of
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